<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004110</url>
  </required_header>
  <id_info>
    <org_study_id>MSKCC-IRB-99033</org_study_id>
    <secondary_id>CDR0000067333</secondary_id>
    <secondary_id>NCI-G99-1599</secondary_id>
    <nct_id>NCT00004110</nct_id>
  </id_info>
  <brief_title>Monoclonal Antibody Therapy Plus Etoposide in Treating Patients With Neuroblastoma</brief_title>
  <official_title>Monoclonal Antibody 3F8 and Oral Etoposide for the Treatment of Neuroblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor&#xD;
      killing substances to them without harming normal cells. Drugs used in chemotherapy use&#xD;
      different ways to stop tumor cells from dividing so they stop growing or die. Combining&#xD;
      monoclonal antibody therapy with chemotherapy may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of monoclonal antibody therapy plus&#xD;
      etoposide in treating patients who have neuroblastoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the antitumor effects of monoclonal antibody 3F8, etoposide, and isotretinoin&#xD;
           using standard imaging methods and tumor marker studies in patients with high-risk&#xD;
           neuroblastoma.&#xD;
&#xD;
        -  Assess progression-free survival in these patients after this treatment.&#xD;
&#xD;
        -  Assess the effects of oral etoposide on human anti-mouse antibody and anti-idiotype&#xD;
           response in these patients.&#xD;
&#xD;
      OUTLINE: Patients are stratified according to disease status (evaluable but not measurable vs&#xD;
      second or subsequent remission with no measurable or evaluable disease).&#xD;
&#xD;
      Patients receive monoclonal antibody 3F8 (MOAB 3F8) IV over 1.5 hours once daily on days 1-10&#xD;
      and oral etoposide once daily on days 29-49. Treatment repeats every 8 weeks for 4 courses in&#xD;
      the absence of disease progression, human anti-mouse antibody (HAMA) response, or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      If HAMA fails to develop after completion of 4 courses of MOAB 3F8, patients continue&#xD;
      treatment with MOAB 3F8 on days 1-5 every 8 weeks until HAMA reaches greater than 1,000 U/mL&#xD;
      or until month 24, whichever occurs first.&#xD;
&#xD;
      Beginning after completion of 4 courses of etoposide and MOAB 3F8 or if HAMA develops,&#xD;
      patients receive oral isotretinoin twice daily for 14 days followed by at least a 14-day&#xD;
      rest. Treatment repeats for a total of 6 courses.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 50 patients (25 per stratum) will be accrued for this study&#xD;
      within 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 1999</start_date>
  <primary_completion_date type="Actual">September 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Neuroblastoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>monoclonal antibody 3F8</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>isotretinoin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  High-risk neuroblastoma by:&#xD;
&#xD;
               -  Histopathology OR&#xD;
&#xD;
               -  Bone marrow involvement plus elevated urinary catecholamines&#xD;
&#xD;
          -  Prior tumor progression on standard chemotherapy and poor long-term prognosis as&#xD;
             indicated by 1 or more of the following:&#xD;
&#xD;
               -  N-myc amplification in tumor cells&#xD;
&#xD;
               -  Diploid chromosomal content plus lp loss of heterozygosity in tumor cells&#xD;
&#xD;
               -  Distant skeletal metastases&#xD;
&#xD;
               -  Unresectable primary tumor infiltrating across the midline&#xD;
&#xD;
               -  More than 10% tumor cells in bone marrow&#xD;
&#xD;
               -  Less than 30% chance of long-term progression-free survival&#xD;
&#xD;
          -  Evaluable (microscopic marrow metastasis, elevated tumor markers, abnormal bone scan&#xD;
             or MIBG or PET scan) but not measurable (CT scan, MRI) disease documented at least 4&#xD;
             weeks after completion of prior systemic therapy&#xD;
&#xD;
          -  No rapidly progressive disease as defined by 1 or more of the following:&#xD;
&#xD;
               -  Serum lactic dehydrogenase greater than 1.5 times upper limit of normal due to&#xD;
                  tumor&#xD;
&#xD;
               -  An opiate requirement for pain from tumor&#xD;
&#xD;
               -  Greater than 25% increase in tumor by successive imaging studies&#xD;
&#xD;
               -  Life expectancy less than 8 weeks&#xD;
&#xD;
          -  Second or subsequent remission after chemotherapy and/or radiotherapy allowed provided&#xD;
             there is less than 30% chance of survival&#xD;
&#xD;
          -  No prior myelodysplastic syndromes or leukemia&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 8 weeks&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  No grade 3 or worse liver toxicity&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  No grade 3 or worse renal toxicity&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No grade 3 or worse cardiac toxicity&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No grade 3 or worse pulmonary toxicity&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  No grade 3 or worse gastrointestinal toxicity&#xD;
&#xD;
          -  No grade 3 or worse neurologic system toxicity&#xD;
&#xD;
          -  No grade 4 hearing deficit&#xD;
&#xD;
          -  No active life-threatening infection&#xD;
&#xD;
          -  No prior exposure to mouse antibodies and human anti-mouse antibody greater than 1,000&#xD;
             ELISA units/mL&#xD;
&#xD;
          -  No allergy to mouse proteins&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nai-Kong V. Cheung, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <study_first_submitted>December 10, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>October 30, 2013</last_update_submitted>
  <last_update_submitted_qc>October 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 31, 2013</last_update_posted>
  <keyword>regional neuroblastoma</keyword>
  <keyword>disseminated neuroblastoma</keyword>
  <keyword>recurrent neuroblastoma</keyword>
  <keyword>localized unresectable neuroblastoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Isotretinoin</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

